Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases

BackgroundToll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal for immunotherapy of cancer Jg. 12; H. 7; S. e008837
Hauptverfasser: Ghosh, Chandra C, Cournoyer, Lauren, Liu, Yujia, Ballarin, Alizee, Layman, Ilan B, LaPorte, Jason, Morrissey, Molly, Fraser, Kayla, Perati, Shriya, Cox, Bryan F, Yakirevich, Evgeny, Treaba, Diana O, Murtha, Timothy D, Guha, Prajna, Katz, Steven C, Davar, Diwakar
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England BMJ Publishing Group Ltd 22.07.2024
BMJ Publishing Group LTD
BMJ Publishing Group
Schlagworte:
ISSN:2051-1426, 2051-1426
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!